Stockscreener 앱 받기
8.80
2.66%
-0.23
전일 마감가:
$9.03
열려 있는:
$8.91
하루 거래량:
31,182
Relative Volume:
0.24
시가총액:
$2.94B
수익:
$417.75M
순이익/손실:
$32.27M
주가수익비율:
90.26
EPS:
0.0975
순현금흐름:
-
1주 성능:
-9.10%
1개월 성능:
-5.89%
6개월 성능:
-45.37%
1년 성능:
-44.23%
1일 변동 폭
$8.78
$8.91
1주일 범위
$8.79
$10.03
52주 변동 폭
$8.76
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
8.7875 | 3.02B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.92 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.00 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
842.75 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.06 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.73 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 개시 | H.C. Wainwright | Buy |
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
TLX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX - GlobeNewswire Inc.
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Finviz
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit - Stock Titan
Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors After Class Action Filing - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing - Stock Titan
Telix Pharmaceuticals Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsTLX - Stock Titan
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action InvestigationTLX - cnhinews.com
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
TLX Investor News: If You Have Suffered Losses in Telix - GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
About Us - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - cnhinews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX | Salt Lake City News, Weather, Sports, Breaking News | KUTV - FinancialContent
Telix stock plunges after FDA issues Complete Response Letter - Investing.com
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
1.23%
자본화:
|
볼륨(24시간):